The overexpression of β-catenin protein in the hBM-MSCs-conditioned AML cell line was inhibited when the hBM-MSCs-conditioned AML cell line was treated with a PI3K/AKT signaling inhibitor LY294002, although Gal-3 protein expression remained unaffected [107]. Here, AKT1 is linked to acute myeloid leukemia.